Abstract
Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.
Original language | English (US) |
---|---|
Pages (from-to) | 1333-1339 |
Number of pages | 7 |
Journal | Vaccine |
Volume | 27 |
Issue number | 9 |
DOIs | |
State | Published - Feb 25 2009 |
Externally published | Yes |
Keywords
- Gastrointestinal disease
- Oral poliovirus
- Rotavirus
- Vaccine
ASJC Scopus subject areas
- Molecular Medicine
- Immunology and Microbiology(all)
- veterinary(all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases